A subsequent post hoc analysis by asthma severity revealed significant clinical benefits in actively treated subjects with moderate , persistent asthma at baseline -LSB- @-@g budesonide/day ( n = @ ) -RSB- , with greater achievement of well-controlled asthma ( @ % and @ % for the active treatment and placebo groups , respectively ; P = @ ) and totally controlled asthma ( @ % and @ % , respectively , P = @ ) , a higher percentage of patients with an asthma control questionnaire score < @ ( @ % and @ % , respectively ; P = @ ) and a greater mean reduction in inhaled corticosteroid use ( @ g and @ g , respectively ; P = @ ) .